Drug Trial News

RSS

Pfizer and Medivation drop further testing of failed Alzheimer’s drug

A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors.

18 Jan 2012

Cangrelor allows stent patients to be 'bridged' to cardiac surgery

New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor has the unique properties of achieving very fast blood thinning effects when needed to protect from heart attacks, but also dissipates rapidly so patients can undergo surgery without the excessive bleeding often associated with blood thinning medications.

18 Jan 2012

New combination treatment more effective in treating cutaneous T-Cell lymphoma

Promising findings on a novel combination treatment approach for a chronic type of skin lymphoma are being published in JAMA's Archives of Dermatology by clinical researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine.

18 Jan 2012

Pfizer, Medivation report results from dimebon Phase 3 trial on AD

Medivation, Inc. and Pfizer Inc. today announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer's disease.

18 Jan 2012

Novelos initiates enrollment in HOT Phase 1b trial for advanced solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that it has enrolled the first patient in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound (131)I-CLR1404 (HOT) in cancer patients with advanced solid tumors.

18 Jan 2012

Regorafenib lengthens lives of patients with metastatic colorectal cancer

An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.

17 Jan 2012

BJALCF receives $1 million in grants for 2012 Lung Cancer Research

Just two months shy of marking its 7-year anniversary, BJALCF announced today that it has awarded over $1 million in grants for 2012 Lung Cancer Research. BJALCF has made a promise to the Lung Cancer Community to fund only immediate results-oriented projects or programs promising to catalyze progress through early detection, genetic testing, drug discovery and patient-focused outcomes.

17 Jan 2012

Pevion announces further data from clinical study of PEV7 therapeutic Candida vaccine

Pevion Biotech AG today announced further data from the ongoing clinical study of its therapeutic Candida vaccine PEV7, demonstrating the generation of specific and functional B cell memory in 100% of vaccinees. Furthermore, the results again confirm the capability of Pevion's second generation virosomal vaccine platform to induce strong and long-lasting immunity in humans against otherwise weak antigens .

17 Jan 2012

Combination of lapatinib and trastuzumab more effective in treating HER2-positive breast cancer

Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent. In a report in the January 17 issue of The Lancet, an international research team reports that a protocol adding lapatinib (Tykerb) to trastuzumab (Herceptin) was more effective than single-drug treatment with either drug in eliminating microscopic signs of cancer at the time the tumors were surgically removed.

17 Jan 2012

MYTHOS clinical trial demonstrates superiority of RenalGuard in reducing CIN

PLC Systems Inc., a company focused on innovative medical device technologies, today announced that final results from the MYTHOS investigator-sponsored clinical trial of RenalGuard in Italy have been published in the January 2012 issue of JACC – Cardiovascular Interventions, a peer-reviewed journal of the American College of Cardiology.

13 Jan 2012

Researchers publish first detailed figures that show risk of Rasilez and ACE inhibitors or ARBs

Researchers at St. Michael's Hospital have published the first detailed figures showing the risk of using the prescription drug Rasilez in combination with certain other blood pressure-lowering medications.

13 Jan 2012

Cabazitaxel with IMRT, androgen deprivation therapy may extend survival for prostate cancer patients

Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients.

13 Jan 2012

Sangart commences MP4CO Phase 1b study in sickle cell disease

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 1b study designed to evaluate the safety of MP4CO treatment in patients with sickle cell disease.

12 Jan 2012

$Merrimack commences MM-151 Phase 1 trial in refractory advanced solid tumors$

Merrimack commences MM-151 Phase 1 trial in refractory advanced solid tumors

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.

11 Jan 2012

Oramed files provisional patent application with USPTO for combination diabetes therapy

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.

11 Jan 2012

Inherited breast and ovarian cancer drug trial re-launched in tablet form

Cancer Research UK's Drug Development Office has re-launched a trial of a promising drug to treat inherited breast and ovarian cancer - but this time taken as a tablet by outpatients.

11 Jan 2012

Starpharma receives FDA Special Protocol Assessment for bacterial vaginosis phase 3

Starpharma today announced that it has received final written agreement from the FDA on the design of its Phase 3 clinical studies of VivaGel® for the treatment of bacterial vaginosis (BV) under the FDA’s Special Protocol Assessment (SPA) scheme.

10 Jan 2012

Study confirms safety and effectiveness of rAHF-PFM in managing hemophilia A

A Rush University Medical Center led international research team has announced that a treatment to prevent bleeding episodes in children with hemophilia A also is effective for adolescents and adults.

10 Jan 2012

Amylin outlines key strategic priorities for 2012

Amylin Pharmaceuticals, Inc. today outlined its key strategic priorities for 2012, with a strong focus on driving the global commercial value of its diabetes franchise.

10 Jan 2012

Positive interim data from Idenix IDX184 12-week phase IIb trial on HCV

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection.

9 Jan 2012